Scarica l'app Stockscreener
1.18
0.00%
0.00
Dopo l'orario di chiusura:
1.19
0.01
+0.85%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.18
Aprire:
$1.19
Volume 24 ore:
251.93K
Relative Volume:
2.27
Capitalizzazione di mercato:
$69.90M
Reddito:
-
Utile/perdita netta:
$-25.65M
Rapporto P/E:
-3.0256
EPS:
-0.39
Flusso di cassa netto:
$-24.59M
1 W Prestazione:
-9.92%
1M Prestazione:
-8.53%
6M Prestazione:
-5.60%
1 anno Prestazione:
+34.58%
Intervallo 1D:
$1.14
$1.22
Intervallo di 1 settimana:
$1.14
$1.32
Portata 52W:
$0.84
$7.80
Vivani Medical Inc Stock (VANI) Company Profile
Nome
Vivani Medical Inc
Settore
Industria
Telefono
818-833-5000
Indirizzo
1350 S. LOOP ROAD, ALAMEDA
Confronta VANI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VANI
Vivani Medical Inc
|
1.18 | 69.90M | 0 | -25.65M | -24.59M | -0.49 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vivani Medical Inc Borsa (VANI) Ultime notizie
Vivani begins exenatide implant trial for obesity in Australia - Yahoo! Voices
Vivani Medical begins first human trial of implantable drug - Investing.com
Vivani Medical Announces Initiation of First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia - Business Wire
EXCLUSIVE: Vivani Medical Initiates First Human Clinical Trial With GLP-1 Implant For Weight Loss In Australia - Yahoo Finance
Vivani Medical to Present at the Innovation in Obesity Therapeutics Summit West Coast - Business Wire
Short Interest in Vivani Medical, Inc. (NASDAQ:VANI) Drops By 29.6% - MarketBeat
Financial Review: Vivani Medical (NASDAQ:VANI) vs. Heyu Biological Technology (OTCMKTS:HYBT) - Defense World
Independent Chairman of the Board of Vivani Medical Gregg Williams Buys 30% More Shares - Simply Wall St
Vivani Medical: Q3 Earnings Snapshot - Darien Times
Vivani Medical Reports Q3 Loss, Advances GLP-1 Trials - TipRanks
Vivani Medical, Inc. (NASDAQ:VANI) Director Gregg Williams Purchases 3,968,253 Shares - MarketBeat
Vivani medical director Gregg Williams buys $5 million in stock By Investing.com - Investing.com Nigeria
Vivani medical director Gregg Williams buys $5 million in stock - Investing.com India
Vivani Medical Secures Funding for GLP-1 Implant Trial - TipRanks
Vivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial Results - Business Wire
Vivani Medical (NASDAQ:VANI) Now Covered by HC Wainwright - Defense World
HC Wainwright & Co. Initiates Coverage of Vivani Medical (VANI) with Buy Recommendation - MSN
3 US Penny Stocks To Monitor In October 2024 - Simply Wall St
Vivani Medical to Present at the Partnership Opportunities in Drug Delivery (PODD) Event and ThinkEquity Conference in October 2024 - Business Wire
Vivani Medical's Market Cap Up US$6.6m Following Year Of Insider Stock Buying - Simply Wall St
Vivani Medical (NASDAQ:VANI) Shares Up 0.9%Here's Why - MarketBeat
Vivani Medical's chief business officer buys shares worth $2,835 - Investing.com India
Vivani Medical's chief business officer buys shares worth $2,835 By Investing.com - Investing.com Australia
Thursday's Insider Trading Moves: Top Buys and Sells in US Stocks - Investing.com India
Precision Optics (OTCMKTS:PEYE) & Vivani Medical (NASDAQ:VANI) Head-To-Head Analysis - Defense World
Vivani Medical (NASDAQ:VANI) Stock Quotes, Forecast and News Summary - Benzinga
Vivani Medical obtains Australian approval to begin GLP-1 implant trial - Yahoo Finance
Vivani Medical's implant trial gets Australian regulatory nod - Investing.com Australia
Vivani Medical's implant trial gets Australian regulatory nod By Investing.com - Investing.com Canada
Vivani Medical to Test Implant in Obese and Overweight Patients - Yahoo Finance
Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia - Business Wire
EXCLUSIVE: Vivani Medical Advances Its Obesity Treatment Implant With New Clinical Trial in Australia - Yahoo Finance
Ventyx deal a sign of Sanofi’s growing interest neuro-immunology? - BioCentury
Sanofi gains exclusivity rights to Ventyx’s CNS-penetrant drug in $27m deal - Yahoo! Voices
Ventyx stock climbs 8% on $27M Sanofi investment - MSN
Sanofi scoops negotiation rights to Ventyx obesity, Parkinson's candidate for $27M - Fierce Biotech
Vicebio secures $100m to advance RSV and hMPV vaccine combo to Phase I - Pharmaceutical Technology
Vivani Medical to Present at the Emerging Growth Conference on September 25, 2024 - Business Wire
Ventyx Biosciences Shares Rise Premarket on Sanofi Investment - Marketscreener.com
Commonwealth Equity Services LLC Has $416,000 Stock Position in Vivani Medical, Inc. (NASDAQ:VANI) - Defense World
Viva Leisure Continues Share Buy-Back Initiative - TipRanks
First Eagle Investment Management LLC Purchases New Holdings in Silvaco Group, Inc. (NASDAQ:SVCO) - MarketBeat
Form 425 Revelyst, Inc. Filed by: Vista Outdoor Inc. - StreetInsider.com
Vista Outdoor Board of Directors Sends Letter to Stockholders Highlighting Reasons to Vote FOR Value Maximizing CSG Transaction - Yahoo Finance
Viva Leisure Continues Share Buy-Back Effort - TipRanks
Vista Outdoor considering sale of Revelyst, urges transaction with CSG - MSN
Vista Outdoor considering sale of Revelyst, urges transaction with CSG (VSTO) - Seeking Alpha
Vivani Medical (NASDAQ:VANI) Shares Down 2.3% - MarketBeat
Vivani Medical Inc Azioni (VANI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):